Nordic Nanovector
Mr. Ludvik Sandnes joined Nordic Nanovector in February 2023 as interim CEO and CFO.
This person is not in any teams
This person is not in any offices
Nordic Nanovector
Nordic Nanovector is committed to developing and delivering innovative therapies to patients to address major unmet medical needs. The Company aspires to become a leader in the development of CD37-targeted therapies for hematological cancers and immune diseases.